Last reviewed · How we verify
NM-IL-12 and TSEBT
At a glance
| Generic name | NM-IL-12 and TSEBT |
|---|---|
| Also known as | HemaMax, rHu-IL12, LD-TSEBT |
| Sponsor | Neumedicines Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NM-IL-12 and TSEBT CI brief — competitive landscape report
- NM-IL-12 and TSEBT updates RSS · CI watch RSS
- Neumedicines Inc. portfolio CI